Basic Information
| LncRNA/CircRNA Name | BALR-2 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | B-lymphoblastic leukemia |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR, Western blot etc. |
| Sample | blood, cell line (HEK 293T) |
| Expression Pattern | differential expression |
| Function Description | high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. In line with a function for this lncRNA in regulating cell survival, BALR-2 knockdown led to reduced proliferation, increased apoptosis, and increased sensitivity to prednisolone treatment. Conversely, overexpression of BALR-2 led to increased cell growth and resistance to prednisone treatment. Interestingly, BALR-2 expression was repressed by prednisolone treatment and its knockdown led to upregulation of the glucocorticoid response pathway in both human and mouse B-cells |
| Pubmed ID | 25681502 |
| Year | 2015 |
| Title | LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia |
External Links
| Links for BALR-2 | GenBank HGNC NONCODE |
| Links for B-lymphoblastic leukemia | OMIM COSMIC |